

Testing for Targeted Therapy of Non-Small-Cell Lung Cancer

Policy Number: AHS – M2030 – Testing for Targeted Therapy of Non-Small-Cell Lung Cancer	Policy Revision Date: 10/15/2025 Initial Policy Effective Date: 12/01/2024
---	---

[POLICY DESCRIPTION](#) | [RELATED POLICIES](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [TABLE OF TERMINOLOGY](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Non-small cell lung cancer (NSCLC) is a heterogeneous group of cancers encompassing any type of epithelial lung cancer, other than small cell lung cancer (SCLC), which arise from the epithelial cells of the lung and include squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.¹ Recently, oncogenesis in NSCLC has been associated with mutations in the epidermal growth factor receptor (*EGFR*), or rearrangements of the anaplastic lymphoma kinase (*ALK*) gene or *ROS1* gene.²

For guidance concerning the use of circulating tumor cells in NSCLC, please refer to AHS-G2054-Liquid Biopsy. For guidance concerning Tumor Mutational Burden Testing (TMB) and/or Microsatellite instability (MSI) analysis, please refer to AHS-M2178-Microsatellite Instability and Tumor Mutational Burden Testing policy.

II. Related Policies

Policy Number	Policy Title
AHS-G2054	Liquid Biopsy
AHS-M2029	Molecular Testing for Cutaneous Melanoma
AHS-M2078	Genetic Testing for Germline Variants of the RET Proto-Oncogene
AHS-M2160	Molecular Testing for Pulmonary Disease
AHS-M2178	Microsatellite Instability and Tumor Mutational Burden Testing

III. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the “Applicable State and Federal Regulations” section of this policy document.

- 1) For individuals with non-small cell lung cancer (NSCLC), single gene testing or broad molecular profiling of the tumor tissue to identify established actionable driver mutations (see Note 1) **MEETS COVERAGE CRITERIA.**
- 2) To direct therapy in patients with NSCLC, analysis of PD-L1 expression by immunohistochemistry **MEETS COVERAGE CRITERIA.**

- 3) As a routine stand-alone assay and as a sole determinant of targeted therapy, *KRAS* molecular testing **DOES NOT MEET COVERAGE CRITERIA.**

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

- 4) To direct targeted therapy for individuals with NSCLC, the following testing **DOES NOT MEET COVERAGE CRITERIA:**
- a) Single gene analysis for genetic alterations not found in Note 1.
 - b) Broad molecular profiling panels that do not include the minimum genetic variants addressed in Note 1.

NOTES:

Note 1: When broad molecular profiling is performed in individuals with NSCLC, the molecular profiling panel must at minimum include the following genetic variants: *ALK* rearrangements, *BRAF* mutations, *EGFR* mutations, *ERBB2 (HER2)* mutations, *KRAS* mutations, *MET*ex14 skipping mutations, *NTRK1/2/3* gene fusions, *RET* rearrangements, and *ROS1* rearrangements. It is recommended that the profiling panel also include emerging biomarkers for which effective therapy may be available (e.g., high-level *MET* amplifications).

Note 2: For two or more gene tests being run on the same platform, please refer to AHS-R2162 Reimbursement Policy.

IV. Table of Terminology

Term	Definition
<i>AKT1</i>	<i>AKT serine/threonine kinase 1 gene</i>
<i>ALK</i>	<i>Anaplastic lymphoma kinase</i>
AMP	Association for Molecular Pathology
ARMS	Amplification Refractory Mutation System
ASCO	American Society of Clinical Oncology
<i>BRAF</i>	<i>B-Raf proto-oncogene serin/threonine kinase gene</i>
CAP	College Of American Pathologists
<i>CD74</i>	<i>Cluster of differentiation 74</i>
cfDNA	Cell-free deoxyribose nucleic acid
CGP	Comprehensive genomic profiling
CLIA	Clinical Laboratory Improvement Amendment Of 1988
CMS	The Centers for Medicare and Medicaid
CNS	Central nervous system
ctDNA	Circulating tumor deoxyribose nucleic acid
DCB	Durable clinical benefit
DNA	Deoxyribose nucleic acid

EGFR	<i>Epidermal Growth Factor Receptor gene</i>
ERBB2	<i>Erythroblastic oncogene B</i>
ERBB2(HER2)	<i>Erythroblastic oncogene B (Human epidermal growth factor receptor 2)</i>
ESMO	European Society for Medical Oncology
FBXW7	<i>F-Box and WD repeat domain containing 7</i>
FDA	Food and Drug Administration
FIG	fluoroethyl-L-tyrosine in glioblastoma
FISH	Fluorescence in situ hybridization
HER2	<i>Human epidermal growth factor receptor 2</i>
HGF	Hepatocyte growth factor
IASLC	International Association for the Study of Lung Cancer
ICI	Immune checkpoint inhibitor
IHC	Immunohistochemistry
KRAS	<i>Kirsten rat sarcoma viral oncogene homolog</i>
LDT	Laboratory-developed test
MAPK	Mitogen-activated protein kinase
MET	<i>MET Proto-Oncogene, Receptor Tyrosine Kinase</i>
MSI	Microsatellite instability
NCCN	National Comprehensive Cancer Network
NDB	No durable benefit
NGS	Next-generation sequencing
NICE	National Institute for Health and Care Excellence
NOS	Not otherwise specified
NSCLC	Non-small cell lung cancer
NTRK	<i>Neurotrophic tyrosine receptor kinase gene</i>
ODxT	Oncomine Dx Target
OH	Ontario Health
PBRM1	<i>Protein Polybromo-1 gene</i>
PCR	Polymerase chain reaction
PD-L1	Programmed death-ligand 1
PFS	Progression-free survival
PI3K	Phosphatidyl 3-kinase (Pi3K)
PIK3CA	<i>Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha gene</i>
PTEN	<i>Phosphatase and TENsin homolog deleted on chromosome 10 gene</i>
pts	Patients
RAS	<i>Rat sarcoma virus gene</i>
RET	<i>Rearranged during transfection gene</i>
ROS1	<i>ROS proto-oncogene 1</i>
RT-PCR	Real-time polymerase chain reaction
SCLC	Small-cell lung cancer
SETD2	<i>SET Domain Containing 2, Histone Lysine Methyltransferase</i>

<i>STK11</i>	<i>Serine/threonine kinase 11 gene</i>
TMB	Tumor mutational burden
<i>TP53</i>	<i>Tumor protein p53 gene</i>
<i>TSC2</i>	<i>TSC complex subunit 2 gene</i>

V. Scientific Background

Primary lung cancer is one of the most common malignancies. In the United States, approximately 226,650 individuals are diagnosed and more than 124,730 deaths occur annually. Approximately 87% of lung cancers are NSCLC, and 13% are SCLC.³

Specific molecular treatments for patients based on certain genetic mutations have been developed. Currently, *EGFR*-, *ALK*-, *ROS1*-, *BRAF*-, and *NTRK*-positive cases of NSCLC have FDA-approved targeted therapies (i.e., specific treatments for specific mutations), whereas *HER2*-, *MET*-, and *RET*-positive cases are treated with off-label therapies. Therapies for other mutations such as *RAS*, *PTEN*, *AKT1*, and *PIK3CA* mutations are currently in development. Still, other genetic biomarkers, such as PD-L1 expression and microsatellite instability (MSI) testing may contribute to the management of NSCLC cases.²

EGFR tyrosine kinase mutations are observed in approximately 15% of NSCLC adenocarcinoma cases in the United States and occur more frequently in nonsmokers. The presence of an *EGFR* mutation usually confers a better prognosis and may be treated by *EGFR* tyrosine kinase inhibitors (TKIs) such as erlotinib.²

ALK tyrosine kinase translocations are present in approximately 4% of NSCLC adenocarcinoma cases in the United States and occur more frequently in nonsmokers and younger patients. In advanced-stage NSCLC, the presence of an *ALK* translocation may be treated by *ALK* TKIs such as crizotinib. Other effective TKIs include ceritinib, alectinib, brigatinib, and lorlatinib.² Studies have indicated that treatment with these therapeutic TKIs significantly prolongs progression-free survival.

ROS1 is a receptor tyrosine kinase that acts as a driver oncogene in one to two percent of NSCLC cases by a translocation between *ROS1* and other genes such as *CD74*. *ROS1* translocations are usually associated with younger patients and individuals who have never smoked tobacco. Since the *ALK* and *ROS* tyrosine kinases are significantly homologous, the *ROS1* tyrosine kinase is treatable by *ALK* TKIs such as crizotinib.²

HER2 (*ERBB2*) is an *EGFR* family receptor tyrosine kinase. Mutations in *HER2* have been detected in approximately one to three percent of NSCLC tumors. These mutations are most frequent in exon 20, resulting primarily in adenocarcinomas and these mutations are more prevalent among individuals who have never smoked tobacco.²

BRAF is a downstream signaling mediator of *KRAS* that activates the mitogen-activated protein kinase (MAPK) pathway. Activating *BRAF* mutations have been observed in one to three percent of NSCLC cases and are usually associated with smokers. *BRAF* inhibition with oral small-molecule TKIs has been used to treat this version of NSCLC.²

MET is a tyrosine kinase receptor for hepatocyte growth factor (HGF). *MET* mutations include *MET* exon 14 skipping, *MET* gene amplification, and *MET* and *EGFR* co-mutations. Tepotinib has shown evidence of promise in treating *MET*-exon 14 skipping cases. Crizotinib, an *ALK*/*ROS* inhibitor, has also been used

to treat *MET*-exon 14 skipping cases of NSCLC. Other *MET*-specific therapies are under investigation such as glesatinib and savolitinib. For those with *MET* amplification, capmatinib or crizotinib are suggested lines of treatment, but are not yet approved for this indication by the FDA and continue to be a line of active research.²

The *RET* gene encodes a cell surface tyrosine kinase receptor that may be translocated in adenocarcinomas. These mutations occur more frequently in younger patients and in individuals who have never smoked tobacco. Off-label *RET* inhibitors, such as alectinib, have been used to treat *RET*-positive cases of NSCLC. In addition, the FDA has approved selpercatinib and pralsetinib for advanced NSCLC in adult patients.²

RAS mutations, in either *KRAS* or *NRAS*, are associated with NSCLC. Activating *KRAS* mutations have been observed in approximately 20 to 25% of lung adenocarcinomas in the United States and are generally associated with smoking. The presence of a *KRAS* mutation has a limited effect on overall survival in patients with early-stage NSCLC. *NRAS* is homologous to *KRAS* and associated with smoking as well; however, *NRAS* mutations comprise only 1% of NSCLC cases. The clinical significance of *NRAS* mutations is unclear, and no effective targeted therapies exist at this time.²

PIK3CA, *AKT1*, and *PTEN* are three genes involved in the same pathway. *PIK3CA* encodes the catalytic subunit of phosphatidylyl 3-kinase (PI3K), *AKT1* acts immediately downstream of PI3K, and phosphatase and tensin homolog (*PTEN*) inhibits *AKT* by dephosphorylation. Oncogenic alterations in this pathway include gain-of-function mutations in *PIK3CA* and *AKT1*, and loss of *PTEN* function. *PIK3CA* mutations may also cause resistance to *EGFR* TKIs in *EGFR*-mutated NSCLC. Small-molecule inhibitors of PI3K and *AKT* are being developed, but clinical efficacy of these agents against specific molecular alterations is unknown.²

Other genetic biomarkers include PD-L1 assessment and microsatellite instability (MSI) testing. Programmed death-1 ligand (PD-L1) expression testing via immunohistochemistry (IHC) is used to guide therapy for patients with NSCLC. Tumor cells present PD-L1 to T-cells to inhibit the immune response by downregulating cytokine production and T-cell proliferation, thereby allowing these tumor cells to evade immune system activity. Monoclonal antibody therapy (immune therapy) has been developed to inhibit this pathway and overcome this mechanism of immune system evasion.⁴ Tumor PD-L1 protein expression through immunohistochemistry can be ordered to pinpoint first-line treatment options for NSCLC outside of chemotherapy.²

Microsatellites are short tandem repeat sequences located throughout the genome. However, these sequences are subject to instability caused by faulty mismatch repair genes. This has historically been reported in other cancers, such as Lynch syndrome, and has been reported in NSCLC. MSI testing may be used to evaluate NSCLC cases.⁵

Precision oncology is now the evidence-based standard of care for the management of many advanced NSCLCs. Expert consensus guidelines have defined minimum requirements for routine testing and identification of *EGFR* and *ALK* mutations in advanced lung adenocarcinomas. Targeted use of TKIs based on certain genetic mutations has consistently led to more favorable outcomes compared with traditional cytotoxic agents.⁶ The concept of targeted testing has been approved by the FDA, as package inserts for drugs such as erlotinib specify used for *EGFR* mutations and other drugs such as pembrolizumab have gained approval for specific types of tumors (in this case, high-MSI tumors).⁷⁻⁹ Proprietary tests are available for identification of relevant mutations, including larger genetic panels. FoundationOne's 324-

gene panel and Oncomine's 23-gene panel are both FDA-approved as companion diagnostics for non-small cell lung cancer targeted therapies.¹⁰ Recently, Guardant 360 CDx was FDA-approved for use as a companion diagnostic to identify NSCLC patients with *EGFR* mutations who may benefit from Tagrisso (osimertinib).¹¹ The company Cobas has a diagnostic approved to identify patients with metastatic NSCLC who might benefit from Tarceva® (erlotinib) based on formalin-fixed tissue preparation to identify *EGFR* mutation; a Cobas assay was also FDA approved as a companion diagnostic using liquid biopsy and circulating-free tumor DNA.¹²

Clinical Utility and Validity

Lin, et al. (2017) evaluated the association between *EGFR* and *EGFR*-TKI efficacy in stage IV NSCLC patients. In this study, 94 patients were assessed. The authors calculated a 74.5% objective response rate and a 97.9% disease control rate for *EGFR*-TKI treatment. The authors concluded that *EGFR*-TKI therapy resulted in survival benefits for *EGFR*-mutant patients regardless of "gender, smoking history, pathologic type, type of *EGFR* mutations, brain metastasis and timing of targeted therapy."¹³

Li, et al. (2017) examined the effect of number of *EGFR* mutations on the efficacy of *EGFR* TKIs. In this study, 201 patients with *EGFR* mutations were evaluated. These patients were quantitatively separated into "low" and "high" groups based on "amplification refractory mutation system (ARMS) method optimized with competitive blockers and specific mutation quantitation (ARMS+)." The cutoff value was determined by a receiving operating characteristic analysis in a training group and further validated in another group. The investigators found the median progression-free survival (PFS) to be 15 months in the high group compared to two months in the low group. Similar results were reported in the validation group. The authors concluded that the abundance of *EGFR* mutations was significantly associated with objective response to *EGFR* TKIs. However, they also noted the abundance of *EGFR T790M* mutation may adversely affect PFS rather than objective response rate.¹⁴

Wang, et al. (2017) investigated the effect of *ALK* rearrangements on NSCLC patients. The authors reviewed 15 studies including 4981 patients. The study found that *ALK* positive (*ALK*+) patients faced better prognoses (hazard ratio 0.81 of *ALK* negative patients) except in the non-smoking population (hazard ratio 1.65). *ALK*+ patients also experienced a significantly higher objective response rate in pemetrexed-based chemotherapy, but not with *EGFR*-TKI treatment.¹⁵

Gainor, et al. (2016) performed a study evaluating the efficacy of PD-L1 blockades on *EGFR* and *ALK* positive patients. The study evaluated 58 patients; 28 had an *EGFR* or *ALK* mutation whereas 30 were wild-type. The investigators found only one of the 28 patients (3.6%) with either mutation had an objective response whereas seven of the 30 (23.3%) wild-type patients had an objective response.¹⁶

Planchard, et al. (2016) evaluated the efficacy of the FDA-approved combination of daBRAFenib plus trametinib on previously treated BRAF-mutant metastatic NSCLC. The study included 57 patients; 36 of these patients achieved an overall response. However, serious adverse events were reported in 32 of these patients. The authors concluded that this combination may represent a robust therapy with a management safety profile in BRAF-positive NSCLC patients.¹⁷

Singal, et al. (2019) examined the electronic health records (EHR) of 4064 individuals with NSCLC from 275 different oncology practices to explore "associations between tumor genomics and patient characteristics with clinical outcomes..." They note that 21.4% of these individuals had a mutation in *EGFR*, *ALK*, or *ROS1*, and that patients with driver mutations who had targeted therapies had significantly

improved overall survival times than individuals who did not have targeted therapies (median of 18.6 versus 11.4 months, respectively); moreover, a tumor mutational burden (TMB) of 20 or higher was associated with improved overall survival for patients on PD-L1-targeted therapy than those patients with a TMB less than 20. The authors concluded that they replicated similar associations from previous research “between clinical and genomic characteristics, between driver mutations and response to targeted therapy, and between TMB and response to immunotherapy.”¹⁸

Siena, et al. (2019) reported integrated data from three clinical trials focusing on entrectinib. Patients had either *ROS1*-driven or *NTRK*-driven cases of NSCLC. Out of 53 patients with *ROS1* mutations, approximately 80% responded to entrectinib. Out of 54 patients with *NTRK* mutations, approximately 60% responded. The authors considered entrectinib to be “tolerable with a manageable safety profile”, and concluded that “entrectinib induced clinically meaningful durable responses in [patients] with *ROS1*+ NSCLC or *NTRK*+ solid tumors with or without CNS disease.”¹⁹

Volckmar, et al. (2019) assessed the “feasibility and clinical utility of comprehensive, NGS-based genetic profiling for routine workup of advanced NSCLC.” The authors based their study on the first 3000 patients seen in their facility. Of the patients tested, the authors identified 807 patients eligible for “currently approved, EGFR-/BRAF-/ALK- and *ROS1*-directed therapies,” while 218 additional cases with *MET*, *ERBB2* (HER2) and *RET* alterations could “potentially benefit from experimental targeted compounds.” Other co-mutations such as *TP53* and *STK11* were also frequently identified, which may be potentially useful predictive and prognostic tools. The authors also noted logistical successes, such as reliability, low dropout rate, fast turnaround times, and minimal tissue requirements. Overall, the authors concluded that this diagnostic approach demonstrated “practicability in order to support individualized decisions in routine patient care, enrollment in molecularly stratified clinical trials, as well as translational research.”²⁰

Signorovitch, et al. (2019) aimed to evaluate the “budget impact of increased use of CGP [comprehensive genomic profiling] using a 324-gene panel (FoundationOne) vs non-CGP (represented by a mix of conventional molecular diagnostic testing and smaller NGS hotspot panels) and the number needed to test with CGP to gain 1 life year.” The authors developed a decision analytic model to assess the financial impact of increased CGP in advanced non-small cell lung cancer (NSCLC). The study included two million covered lives, of which 532 had advanced NSCLC. Of these patients, 266 underwent molecular diagnostic testing. An increased in CGP among those tested (from 2%-10%) was associated with a \$0.02 per member per month budget impact, of which \$0.013 “was attributable to costs of prolonged drug treatment and survival and \$0.005 to testing cost.” Overall, the addition of one life year was met with 12 patients tested. The authors concluded that a 2%-10% increase in CGP use was associated with a “modest budget impact, most of which was attributed to increased use of more effective treatment and prolonged survival.”²¹

Peled, et al. (2020) investigated the clinical utility of early cell-free deoxyribose nucleic acid (cfDNA) analysis using Guardant 360 CDx in treatment-naïve NSCLC patients. Ten patients were studied and the median time from blood draw to receiving the cfDNA results was nine days. Actionable biomarkers were identified in four of the ten patients by both biopsy analysis and cfDNA analysis. Overall, three patients received biomarker-based treatment (one osimertinib, one alectinib, and one crizotinib). The authors concluded that “cfDNA analysis should be ordered by the pulmonologists early in the evaluation of patients with NSCLC, which might complement the tumor biopsy.”²²

Al-Ahmadi, et al. (2021) studied the overall impact and racial differences of NGS testing in NSCLC patients. The study tested 295 patients with Stage IV NSCLC using the FoundationOne assay and genomic differences were compared by race. "Patients undergoing NGS testing had significantly longer survival of 25.3 months versus those who did not undergo sequencing with a median survival of 14.6 months (P=.002) irrespective if they received targeted therapy or not." In addition, there was no difference in NGS results based on race. However, African American patients had a higher rate of mutations in *PBRM1*, *SETD2*, *TSC2*, and *FBXW7*. Overall, there is no racial difference in NGS utilization and testing does increase survival.²³

Boeckx, et al. (2020) convened a small study of 46 never-smoking, non-small cell lung cancer (NSCLC) patients to investigate genomic alterations in non-smoking individuals. There are few genomic studies focused primarily on this subgroup of patients with NSCLC who have never smoked. Whole exome and low-coverage whole genome sequencing was performed on tumors and matched germline DNA. Fewer somatic mutations, genomic breakpoints, and a smaller percentage of the genome with chromosomal instability in lung tumors were observed in non-smokers compared to smokers. In addition, *TSC22D1* was noted as a potential driver gene of NSCLC. The frequency of mutation of *TP53*, which is associated with negative long-term outcomes, was lower in those who were never-smokers than in smokers. That said, they found driver genes such as *EGFR* and *ERBB2*, as well as amplifications in *MET* were higher in never-smokers. The authors concluded there was a "more favorable prognosis for never smokers with NSCLC."²⁴

Qi, et al. (2024) studied the clinical validity of the Oncomine Dx Target (ODxT) Test to identify HER2 NSCLC. Tumor samples from patients enrolled in two clinical trials were used. Commercially available tumor samples were also used. The authors compared the results of the Oncomine Dx Target Test with the assay used in the clinical trials. The Oncomine Dx Target Test had a positive percent agreement of 100% and a negative percent agreement of 99.1%. "The ODxT Test results were highly concordant with clinical trial assays." The authors concluded that "The ODxT Test detected HER2 mutations in NSCLC with high analytical and clinical accuracy and identified HER2m populations with response rates similar to populations identified by [clinical trial assays], supporting clinical utility of the ODxT Test to inform treatment decisions for HER2m NSCLC."²⁶

Chen, et al. (2024) studied the clinical validity and utility of circulating tumor DNA (ctDNA) NGS as a tool for targeted treatment of advanced NSCLC. The authors conducted a systematic literature review and meta-analysis including 20 studies. For the detection of any mutation, the sensitivity of ctDNA was 0.69 and the specificity was 0.99. Sensitivity varied by gene: 0.29 for *ROS1*, 0.38 for *RET*, 0.47 for *MET*, 0.59 for *ALK*, 0.60 for *BRAF*, 0.68 for *EGFR*, and 0.77 for *KRAS*. The authors concluded that "ctDNA testing demonstrated an overall acceptable diagnostic accuracy in patients with [advanced NSCLC], however, sensitivity varied greatly by driver mutation."²⁷

VI. Guidelines and Recommendations

National Comprehensive Cancer Network (NCCN)

In the Version 3.2025 update for NSCLC, NCCN states that "Numerous gene alterations have been identified that impact therapy selection. Testing of lung cancer specimens for these alterations is important for identification of potentially efficacious targeted therapies, as well as avoidance of therapies unlikely to provide clinical benefit."²⁸ NCCN then expounds on their stance, providing a set of "several methodologies are generally considerations for use" that is delineated below.

- “Next-generation sequencing (NGS) is used in clinical laboratories. Not all types of alterations are detected by individual NGS assays and it is important to be familiar with the types of alterations identifiable in individual assays or combination(s) of assays.”
- “It is recommended at this time that when feasible, testing be performed via a broad, panel-based approach, most typically performed by NGS. For patients who, in broad panel testing don’t have identifiable driver oncogenes (especially in never smokers), consider RNA-based NGS if not already performed, to maximize detection of fusion event.”
- “Real-time polymerase chain reaction (PCR) can be used in a highly targeted fashion (specific mutations targeted). When this technology is deployed, only those specific alterations that are targeted by the assay are assessed.”
- “Any method that interrogates sequences other than a subset of highly specific alterations (eg, NGS) has the potential to identify variants of uncertain significance (VUS). Any variant classified as a VUS, even if in a gene in which other variants are clinically actionable, should not be considered as a basis for therapy selection.”
- “Other methodologies may be utilized, including multiplex approaches not listed above.”
- “Fluorescence in situ hybridization (FISH) analysis is utilized for many assays examining copy number, amplification, and structural alterations such as gene rearrangements. FISH may have better sensitivity for gene amplification events in some circumstances.”²⁸

In order “To minimize tissue use and potential wastage, the NCCN NSCLC Panel recommends that broad molecular profiling be done as part of biomarker testing using a validated test(s) that assesses a minimum of the following potential genetic variants: *ALK* rearrangements, *BRAF* mutations, *EGFR* mutations, *ERBB2* (HER2) mutations, *KRAS* mutations, *METex14* skipping mutations, *NTRK 1/2/3* gene fusions, *RET* rearrangements, and *ROS1* rearrangements. Both FDA and laboratory-developed test platforms are available that address the need to evaluate these and other analytes. Broad molecular profiling is also recommended to identify rare driver mutations for which effective therapy may be available, such as high-level *MET* amplifications.”²⁸

The NCCN also states that, “First-line targeted therapy options are recommended for eligible patients with metastatic NSCLC and positive test results for actionable driver mutations such as, *ALK*, *BRAF* p.V600E, *EGFR*, *METex14* skipping, *NTRK1/2/3*, *RET*, and *ROS1*. Second-line targeted therapy is recommended for patients with metastatic NSCLC and positive test results for *EGFR exon 20* insertions or *KRAS* p. G12C mutations.”²⁸

In the 2022 NCCN update, the NCCN clarified that “any variant that is classified as VUS should not be used to select targeted therapy even if the VUS occurs in a gene in which other variants are clinically actionable.”²⁸

The NCCN Panel added important information about general standards for biomarker testing in eligible patients with NSCLC. They noted that broad molecular profiling is molecular testing that “identifies all of the classic actionable driver mutations described in the algorithm [eg. *ALK*, *BRAF*, *EGFR*, *ERBB2* (HER2), *KRAS*, *METex14* skipping, *NTRK1/2/3*, *RET*, *ROS1*]—using either a single assay or a combination of a limited number of assays—and optimally also identifies the emerging actionable molecular biomarkers, including high-level *MET* amplification. Tiered *KRAS* testing approaches, based on the low prevalence of co-occurring biomarkers, are acceptable.”²⁸

EGFR mutations

EGFR mutations are most often assessed using RT-PCR, and NGS. *EGFR* mutation status is important for determining use of tyrosine kinase inhibitor (TKI) therapies. *EGFR* mutations include, but are not limited to, exon 19 deletions, p.L858R point mutation, p.L861Q, p.G719X, p.S768I0, exon 20 insertion variants, and p.T790M. As a category 1 recommendation, *EGFR* mutation testing is recommended for advanced or metastatic disease, including adenocarcinoma, large cell, and NSCLC NOS. As a category 2A recommendation, it is recommended to consider it for individuals with squamous cell carcinoma who have never been smokers, small biopsy specimens, or mixed histology.²⁸

ALK gene rearrangements

ALK gene rearrangements are most often assessed using FISH, but IHC can also be effective. The NCCN states that NGS can detect *ALK* fusions, but PCR is less likely to detect any *ALK* fusion with a novel partner(s). The most common fusion partner for *ALK* is *EML4*; however, other partners have been isolated and identified. Like *EGFR*, *ALK* status is used in determining whether TKI therapies are appropriate. As a category 1 recommendation, *ALK* testing is recommended for advanced or metastatic disease, including adenocarcinoma, large cell, and NSCLC NOS. As a category 2A recommendation, it is recommended to consider it for individuals with squamous cell carcinoma who have never been smokers, small biopsy specimens, or mixed histology.²⁸

ROS1 rearrangements

In NSCLC, *ROS1* rearrangements can result in inappropriate *ROS1* kinase signaling. Similar to *ALK*, FISH break-apart testing is often used, but this methodology “may under-detect the *FIG-ROS1* variant.”²⁸ IHC requires confirmatory testing because it has a low specificity for *ROS1*. PCR, if used, can be unlikely to detect novel fusion partners. The use of NGS can detect *ROS1* fusions, but DNA-based NGS is prone to under-detection of *ROS1* fusions. *ROS1* status is important for responsiveness to oral *ROS1* TKIs. As category 2A recommendations, *ROS1* testing should be performed for advanced or metastatic disease, including adenocarcinoma, large cell, and NSCLC NOS; it should be considered in individuals with squamous cell carcinoma with small biopsy specimens or mixed histology. Entrectinib has been noted as a preferred treatment option for *ROS1* rearrangements in advanced or metastatic NSCLC by the NCCN since 2019. However, it should be noted that “Targeted real-time PCR assays are utilized in some settings, although they are unlikely to detect fusions with novel partners.”²⁸

BRAF point mutations

Sequencing methods, especially NGS, and rtPCR are most often used for detecting *BRAF* point mutations. *BRAF* V600 mutations are associated with responsiveness to certain combination therapies. Many *BRAF* mutations have been identified in NSCLC, but the impact of these mutations is not well-understood as of date. As category 2A recommendations, *BRAF* testing should be performed for advanced or metastatic disease, including adenocarcinoma, large cell, and NSCLC NOS; it should be considered in individuals with squamous cell carcinoma with small biopsy specimens or mixed histology.²⁸

KRAS point mutations

Like *BRAF*, sequencing methods are used in the identification of point mutations within the *KRAS* gene. For NSCLC, the most common *KRAS* mutations are located in codon 12 even though other point mutations may occur elsewhere. *KRAS* mutations have been linked as a prognostic indicator of poor survival and can impact *EGFR* TKI therapy. The NCCN states, “*KRAS* mutations do not generally overlap with *EGFR*, *ROS1*, *BRAF*, and *ALK* genetic variants. Therefore, a tiered approach using *KRAS* testing may

identify patients who may not benefit from further molecular biomarker testing.” A newly designed oral KRAS G12C inhibitor was found to be effective in use against the KRAS p.G12C mutation, but this class of inhibitor has not been evaluated for any other mutations.²⁸

MET exon 14 skipping variants

NGS-based testing, particularly RNA-based as it provides improved detection, is used to detect *MET* exon 14 skipping events. Immunohistochemistry is not used. Oral TKI therapy is used to address a *MET* exon 14 skipping mutation when detected. The NCCN states that “NGS-based testing is the primary method for detection of *MET* exon 14 skipping events; RNA-based NGS may have improved detection. IHC is not a method for detection of *MET* exon 14 skipping.”²⁸

RET

FISH break-apart probe methodology is one appropriate method used to detect a *RET* mutation, though it may under-detect some fusions. NCCN also states that “Targeted real-time reverse-transcriptase PCR assays are utilized in some settings, although they are unlikely to detect fusions with novel partners. NGS-based methodology has a high specificity, and RNA-based NGS is preferable to DNA-based NGS for fusion detection.” Sequencing methods such as NGS and rtPCR are effective but rtPCR has difficulty detecting fusions with novel partners. RNA-based NGS has better fusion detection capability than DNA-based NGS. Regardless of fusion partner, *RET* mutations are responsive to oral *RET* TKI therapies.²⁸

ERBB2

The *ERBB2* gene encodes for HER2. *ERBB2* mutations, amplifications, and alterations, have been identified in various tumor types. NCCN states “While targeted PCR techniques can be utilized to examine *ERBB2* mutations, the diversity and spectrum of mutations are best surveyed using NGS-based approaches.” Additionally, “At this time, there is no recommendation regarding specific IHC antibody clone for HER2 staining in NSCLC.”

NTRK gene fusion

The NCCN has an *NTRK* gene fusion positive algorithm where larotrectinib is to be used as a first-line therapy if the gene fusion was discovered prior to first-line systemic therapy. If the *NTRK* gene fusion was discovered during a different first-line systemic therapy, then they recommend completing the planned systemic therapy, including maintenance therapy, and then follow this first-line therapy up with larotrectinib. As a category 2A recommendation, the NCCN recommends *NTRK* gene fusion testing to be included as part of molecular profiling for all forms of advanced or metastatic disease, including adenocarcinoma, large cell, NSCLC NOS, and squamous cell carcinoma. The NCCN NSCLC Panel recommends larotrectinib and entrectinib (both are category 2A) as either first-line or subsequent therapy options for patients with *NTRK* gene fusion-positive metastatic NSCLC based on data and the FDA approvals. As of the v3 2020 update, both agents are considered “preferred” first-line therapies for patients with *NTRK* gene fusion-positive metastatic disease.²⁸

PD-L1

PD-L1 is expressed on tumor cells; its presence is used to determine possible pembrolizumab therapy. The FDA has approved IHC use for assessing PD-L1. The FDA-approved companion diagnostic for PD-L1 guides utilization of pembrolizumab in patients with NSCLC and is based on the tumor proportion score.

As a category 1 recommendation, PD-L1 testing is recommended for all cases of advanced or metastatic disease, including adenocarcinoma, large cell, NSCLC NOS, and squamous cell carcinoma. NCCN states that, in comparison to TMB, “PD-L1 expression level is a more useful immune biomarker than TMB for deciding how to use immunotherapy, because test results are obtained more quickly, less tissue is needed for testing, and data demonstrate relative reproducibility across platforms and individuals.” However, “While some clones for PD-L1 IHC are FDA-approved for specific indications, use of multiple IHC tests is not necessary, provided any individual IHC test has been internally validated for comparability for categorical results against the FDA-approved clone.”²⁸

Tumor Mutational Burden (TMB)

NCCN reports that “In 2020, the NCCN Panel deleted tumor mutational burden (TMB) as an emerging immune biomarker based on clinical trial data and other issues.” Preliminary data from PFS from CHECKMATE 227, a phase 3 randomized trial with a complex design, had suggested that TMB might be a useful immune biomarker for deciding whether to use immunotherapy in patients with metastatic NSCLC, but updated data indicated that “overall survival was improved with nivolumab plus ipilimumab regardless of TMB or PD-L1 expression levels.” Furthermore, “Several trials have shown that high TMB levels do not correlate with PD-L1 expression levels in patients with NSCLC.” This lack of clinical data, coupled with technical problems with measuring TMB—including “1) lack of agreement on the definition of a cut off for designating high TMB levels; and 2) lack of standardization of TMB measurements across laboratories”—drives the NCCN Guidelines to “not recommend measurement of TMB levels before deciding whether to use nivolumab plus ipilimumab regimens or to use other ICIs, such as pembrolizumab.”²⁸

Emerging biomarkers to identify novel therapies

The NCCN lists the following emerging biomarkers to identify novel therapies for patients with metastatic NSCLC.

Genetic Alteration (ie, Driver event)	Available Targeted Agents with Activity Against Driver Event in Lung Cancer
High-level <i>MET</i> amplification	Capmatinib Tepotinib Crizotinib
<i>FGFR</i> alterations	Erdafitinib

College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP)

The CAP/IASLC/AMP joint guidelines indicate that “*EGFR* molecular testing should be used to select patients for *EGFR*-targeted TKI [tyrosine kinase inhibitor] therapy” (Evidence Grade: A) (Lindeman et al, 2013). Testing is recommended for adenocarcinomas and mixed lung cancers “regardless of histologic grade.” However, in the setting of fully excised lung cancer specimens, *EGFR* testing is not recommended for lung cancer without any adenocarcinoma component (Evidence Grade: A). In the setting of more limited lung cancer specimens where an adenocarcinoma component cannot be completely excluded, *EGFR* testing is recommended “in cases showing squamous or small cell histology but clinical criteria (eg, young age, lack of smoking history) may be useful in selecting a subset of these samples for

testing” (Evidence Grade: A)” (Lindeman et al, 2013). The 2018 CAP guidelines reaffirmed the 2013 guideline recommendations of universal testing of lung cancer patients with advanced-stage cancers with an adenocarcinoma component, using molecular diagnosis for activating “hot-spot” mutations in *EGFR* exons 18 to 21 with at least 1% prevalence (ie, codons 709 and 719, exon 19 deletion 768, and exon 20 insertions 790, 858, and 861).²⁹

The CAP also added the recommendation that: “In lung adenocarcinoma patients who harbor sensitizing *EGFR* mutations and have progressed after treatment with an *EGFR*-targeted tyrosine kinase inhibitor, physicians must use *EGFR* T790M mutational testing when selecting patients for third-generation *EGFR*-targeted therapy. Laboratories testing for *EGFR* T790M mutation in patients with secondary clinical resistance to *EGFR* targeted kinase inhibitors should deploy assays capable of detecting *EGFR* T790M mutations in as little as 5% of viable cells.”²⁹

The CAP recommendations were updated to include “3 categories into which genes should be placed. One set of genes must be offered by all laboratories that test lung cancers, as an absolute minimum: *EGFR*, *ALK*, and *ROS1*. A second group of genes should be included in any expanded panel that is offered for lung cancer patients: *BRAF*, *MET*, *RET*, *ERBB2* (*HER2*), and *KRAS*, if adequate material is available...All other genes are considered investigational at the time of publication.” They elaborate to recommend: “In this context, institutions providing care for lung cancer patients have a choice: (1) offer a comprehensive cancer panel that includes all of the genes in the first 2 categories (*EGFR*, *ALK*, *ROS1*, *BRAF*, *MET*, *ERBB2* [*HER2*], *KRAS*, *RET*) for all appropriate patients, or (2) offer targeted testing for the genes in the must-test category (*EGFR*, *ALK*, *ROS1*) for all appropriate patients and offer as a second test an expanded panel containing the second-category genes (*BRAF*, *MET*, *ERBB2* [*HER2*], and *RET*) for patients who are suitable candidates for clinical trials, possibly after performing a single-gene *KRAS* test to exclude patients with *KRAS*-mutant cancers from expanded panel testing.”²⁹ However, the CAP states that “*KRAS* molecular testing is not indicated as a routine stand-alone assay as a sole determinant of targeted therapy. It is appropriate to include *KRAS* as part of larger testing panels performed either initially or when routine *EGFR*, *ALK*, and *ROS1* testing are negative” and that “[*RET*, *MET*, *KRAS*, and *ERBB2* (*HER2*)] molecular testing is not indicated as a routine stand-alone assay outside the context of a clinical trial. It is appropriate to include [*RET*, *MET*, *KRAS*, and *ERBB2* (*HER2*)] as part of larger testing panels performed either initially or when routine *EGFR*, *ALK*, and *ROS1* testing are negative.”²⁹

The guidelines indicate that “*ALK* molecular testing should be used to select patients for *ALK*-targeted TKI therapy” (Evidence Grade: B).³⁰ Testing is recommended for adenocarcinomas and mixed lung cancers “regardless of histologic grade.” However, in the setting of fully excised lung cancer specimens, *ALK* testing is not recommended for lung cancer without any adenocarcinoma component (Evidence Grade: A). In the setting of more limited lung cancer specimens where an adenocarcinoma component cannot be completely excluded, *ALK* testing is recommended “in cases showing squamous or small cell histology but clinical criteria (eg, young age, lack of smoking history) may be useful in selecting a subset of these samples for testing” (Evidence Grade: A).³⁰

The CAP recommends that “Multiplexed genetic sequencing panels are preferred over multiple single-gene tests to identify other treatment options beyond *EGFR*, *ALK*, and *ROS1*.” They found that “NGS

enables the simultaneous assessment of all 3 of the “must-test” genes in lung cancer—*EGFR*, *ALK*, *ROS1*—as well as each of the genes suggested for inclusion in larger panels—*BRAF*, *RET*, *ERBB2 (HER2)*, *KRAS*, *MET*—and hundreds to thousands of other genes that may have potential roles in cancer development. In addition to small mutations, NGS assays can detect fusions/rearrangements and copy number changes in the targeted genes, if designed with these alterations in mind. Numerous studies have demonstrated the excellent sensitivity of NGS methods relative to single-gene targeted assays, particularly for single-nucleotide-substitution mutations. Next-generation sequencing methods typically require less input DNA and can accommodate smaller samples with lower concentrations of malignant cells, and, although typically slower than 1 single-gene assay, can often be performed more rapidly than sequential multiple single-gene assays. A reduced need for repeat biopsy is an additional benefit of panel testing.”²⁹

When asked about new genes that should be tested for in lung cancer patients, CAP strongly recommends that “*ROS1* testing must be performed on all lung adenocarcinoma patients, irrespective of clinical characteristics.”²⁹

Other guidance was backed by expert consensus opinion, and these recommendations include the following:

- “*ROS1* IHC may be used as a screening test in lung adenocarcinoma patients; however, positive *ROS1* IHC results should be confirmed by a molecular or cytogenetic method.”
- “*BRAF* molecular testing is currently not indicated as a routine stand-alone assay outside the context of a clinical trial. It is appropriate to include *BRAF* as part of larger testing panels performed either initially or when routine *EGFR*, *ALK*, and *ROS1* testing are negative.”
- “*RET* molecular testing is not recommended as a routine stand-alone assay outside the context of a clinical trial. It is appropriate to include *RET* as part of larger testing panels performed either initially or when routine *EGFR*, *ALK*, and *ROS1* testing are negative.”
- “*ERBB2 (HER2)* molecular testing is not indicated as a routine stand-alone assay outside the context of a clinical trial. It is appropriate to include *ERBB2 (HER2)* mutation analysis as part of a larger testing panel performed either initially or when routine *EGFR*, *ALK*, and *ROS1* testing are negative.”
- “*KRAS* molecular testing is not indicated as a routine stand-alone assay as a sole determinant of targeted therapy. It is appropriate to include *KRAS* as part of larger testing panels performed either initially or when routine *EGFR*, *ALK*, and *ROS1* testing are negative.”
- “*MET* molecular testing is not indicated as a routine stand-alone assay outside the context of a clinical trial. It is appropriate to include *MET* as part of larger testing panels performed either initially or when routine *EGFR*, *ALK*, and *ROS1* testing are negative.”²⁹

In 2018, CAP added the recommendation that “IHC is an equivalent alternative to FISH for *ALK* testing”, and that “although at the time of writing RT-PCR and NGS are not approved by the FDA in the United States as first-line methods for determining *ALK* status in selection of patients for *ALK* inhibitor therapy, these approaches have shown comparable performance with IHC when designed to detect the majority of fusions, and are standard practice in many other countries. These methods are highly specific for most fusions, and patients with positive results should be treated with an *ALK* inhibitor, although patients

with negative results may benefit from a more sensitive method to exclude the possibility of a variant fusion. Similarly, amplicon-based NGS assays of DNA may likewise fail to detect all fusion variants, and therefore a capture-based DNA or RNA approach is preferred for NGS testing for *ALK* fusions. Current data are still too limited to develop a specific recommendation either for or against the use of NGS for *ALK* fusions as a sole determinant of *ALK* TKI therapy.”²⁹

When performing molecular testing, CAP suggests that “Multiplexed genetic sequencing panels are preferred over multiple single-gene tests to identify other treatment options beyond *EGFR*, *ALK*, and *ROS1*” and that “Laboratories should ensure test results that are unexpected, discordant, equivocal, or otherwise of low confidence are confirmed or resolved using an alternative method or sample.”²⁹

Testing is indicated for patients with targetable mutations who have relapsed on targeted therapy. The CAP notes that

- “In lung adenocarcinoma patients who harbor sensitizing *EGFR* mutations and have progressed after treatment with an *EGFR*-targeted tyrosine kinase inhibitor, physicians must use *EGFR* T790M mutational testing when selecting patients for third-generation *EGFR*-targeted therapy” (strong recommendation); and
- “Laboratories testing for *EGFR* T790M mutation in patients with secondary clinical resistance to *EGFR*-targeted kinase inhibitors should deploy assays capable of detecting *EGFR* T790M mutations in as little as 5% of viable cells” (recommendation).

However, CAP also finds that “There is currently insufficient evidence to support a recommendation for or against routine testing for *ALK* mutational status for lung adenocarcinoma patients with sensitizing *ALK* mutations who have progressed after treatment with an *ALK*-targeted tyrosine kinase inhibitor.”²⁹

Regarding the use of circulating cell-free DNA, CAP claims that “There is currently insufficient evidence to support the use of circulating cell-free plasma DNA molecular methods for the diagnosis of primary lung adenocarcinoma.” Moreover, “There is currently insufficient evidence to support the use of circulating tumor cell molecular analysis for the diagnosis of primary lung adenocarcinoma, the identification of *EGFR* or other mutations, or the identification of *EGFR* T790M mutations at the time of *EGFR* TKI resistance.” However, CAP concedes that “In some clinical settings in which tissue is limited and/or insufficient for molecular testing, physicians may use a cell-free plasma DNA assay to identify *EGFR* mutations” and that “Physicians may use cell-free plasma DNA methods to identify *EGFR* T790M mutations in lung adenocarcinoma patients with progression or secondary clinical resistance to *EGFR*-targeted tyrosine kinase inhibitors; testing of the tumor sample is recommended if the plasma result is negative.”²⁹

American Society of Clinical Oncology (ASCO)

The ASCO published a joint update on “Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations” with Ontario Health (OH). These guidelines are intended for patients without alterations in *EGFR* or *ALK*. These recommendations divide PD-L1 expression into three categories: negative (0%), low positive (1-49%) and high (>50%). Pembrolizumab, carboplatin, pemetrexed, atezolizumab, paclitaxel, and bevacizumab are all listed as potential treatments, some of which may stand alone and some which

are to be used in combination.³¹

Another joint update with Cancer Care Ontario remarked that “Mutations in *KRAS* are not predictive for benefit from adjuvant chemotherapy.”³²

The ASCO published an endorsement of the joint guidelines from the CAP/IASLC/AMP with minor modifications. Relevant differences from the joint guidelines include:

- *BRAF* testing should be performed on all patients with advanced lung adenocarcinoma, irrespective of clinical characteristics.
- Physicians may use molecular biomarker testing in tumors with an adenocarcinoma component or nonsquamous non–small-cell histology (in addition to “any non–small-cell histology when clinical features indicate a higher probability of an oncogenic driver (eg, young age [50 years]; light or absent tobacco exposure).”³³

European Society for Medical Oncology (ESMO)

According to ESMO, genetic alterations, which are key oncogenic events (driver mutations), have been identified in NSCLC, with two of these—*EGFR* mutations and the anaplastic lymphoma kinase (*ALK*) rearrangements—determining approved, selective pathway-directed systemic therapy. The ESMO guidelines do not specifically mention *KRAS* mutation testing. NGS is also mentioned for *ALK*, *RET*, *ROS1*, *MET*, *HER2*, and *BRAF* mutations.³⁴

The ESMO remarks that the role of targeted agents in stages I-III NSCLC have not been evaluated properly. Therefore, they state that “there is no role for targeted agents in stage III NSCLC outside clinical trials.”³⁵

The ESMO published a guideline regarding metastatic NSCLC in 2020. In it, they note *EGFR*, *ALK*, *ROS1*, *BRAF*, and PD-L1 expression as usable biomarkers for “personalised medicine.” *HER2*, *MET*, *NTRK*, and *RET* are considered “evolving targets/biomarkers.” ESMO’s specific recommendations are listed below.

- “*EGFR* mutation status should be systematically analysed in advanced NSCC [non-small cell lung cancer] [level of evidence “I”, strength of recommendation “A”]. Test methodology should have adequate coverage of mutations in exons 18–21, including those associated with resistance to some therapies [III, B]. At a minimum, when resources or material are limited, the most common activating mutations (exon 19 deletion, exon 21 L858R point mutation) should be determined”
- “The availability of TKIs effective against T790M-mutant recurrent disease makes T790M testing on disease relapse mandatory [I, A]”
- “Testing for *ALK* rearrangement should be systematically carried out in advanced non-squamous NSCLC [I, A]”
- “Testing for *ROS1* rearrangement should be systematically carried out in advanced NSCLC [III, A]. Detection of the *ROS1* translocation by FISH remains a standard; IHC may be used as a screening approach [IV, A]”
- “*BRAF* V600 mutation status should be systematically analysed in advanced NSCLC for the prescription of *BRAF*/MEK inhibitors”
- “Molecular *EGFR* and *ALK* testing are not recommended in patients with a confident diagnosis of SCC, except in unusual cases, e.g. never/former light smokers or long-time ex-smokers”

- “If available, multiplex platforms (NGS) for molecular testing are preferable [III, A].”
- “PD-L1 IHC should be systematically determined in advanced NSCLC [I, A]”
- “Testing is required for pembrolizumab therapy but may also be informative when nivolumab or atezolizumab are used.”³⁶

In 2023, ESMO issued clinical practice guidelines focusing on oncogene-addicted metastatic non-small-cell lung cancer. These guidelines include

- “Adequate tissue material for histological diagnosis and molecular testing should be obtained to allow for individual treatment decisions [IV, A].”
- “Pathological diagnosis should be made according to the 2021 World Health Organization classification of lung tumours [IV, A].
- “Specific subtyping of all NSCLCs is necessary for therapeutic decision making and should be carried out wherever possible. IHC stains should be used to reduce the NSCLC-not otherwise specified rate to fewer than 10% of cases diagnosed [IV, A].
- The molecular tests below are recommended in patients with advanced non-squamous-cell carcinoma, and not recommended in patients with a confident diagnosis of squamous-cell carcinoma, except in unusual cases, e.g. young (<50 years) patients, never (<100 cigarettes in a lifetime)/former light smokers (≤15 pack-years, all kinds of tobacco) or long-time ex-smokers (quit smoking >15 years ago, all kinds of tobacco) [IV, A].
- *EGFR* mutation status should be determined [I, A]. Test methodology should have adequate coverage of mutations in exons 18-21, including those associated with resistance to some therapies [III, A]. At a minimum, when resources or material are limited, the most common activating mutations (exon 19 deletion, exon 21 L858R point mutation) should be determined [I, A].
- The availability of TKIs effective against T790M-mutated recurrent disease makes T790M testing on disease relapse on first- or second-generation *EGFR* TKIs mandatory [I, A].
- Testing for *ALK* rearrangements should be carried out [I, A].
- Detection of the *ALK* translocation by FISH remains a standard, but IHC with high-performance *ALK* antibodies and validated assays may be used for screening [III, A] and have been accepted as an equivalent alternative to FISH for *ALK* testing.
- Testing for *ROS1* rearrangements should be carried out [II, A]. Detection of the *ROS1* translocation by FISH remains a standard; IHC may be used as a screening approach [IV, A].
- *BRAF V600* mutation status testing should be carried out [II, A].
- Testing for *NTRK* rearrangements should be carried out [II, A]. Screening for *NTRK* rearrangements may use IHC or NGS, with appropriate testing follow-up to validate a positive result [II, A].
- Testing for *MET* exon 14 skipping mutations, *MET* amplifications, *RET* rearrangements, *KRAS* G12C mutations and *HER2* mutations should be carried out [II, A].
- If available, multiplex platforms (NGS) for molecular testing are preferable [III, A].
- RNA-based NGS is preferred for identifying an expanding range of fusion genes [III, B]. Whichever testing modality is used, it is mandatory that adequate internal validation and quality control measures are in place and that laboratories participate in, and perform adequately in, external quality assurance schemes for each biomarker test [III, A].
- cfDNA (liquid biopsy) can be used to test for oncogenic drivers as well as resistance mutations, but all patients with a negative cfDNA blood test still require tissue biopsy [II, A].”²⁶

In 2024, EMSO released recommendations on the use of NGS in patients with advanced cancer. “ESMO

recommends carrying out multigene NGS in patients with advanced cancers in countries where tumour-agnostic targeted therapies are accessible.” EMSO specifically recommends NGS for patients with advanced non-squamous NSCLC. EMSO also states that “advanced non-squamous NSCLC is the sole indication where the cost-effectiveness of a multigene panel sequencing approach compared with single-marker testing and sequential testing has been demonstrated at acceptable willingness-to-pay thresholds in Europe, Asia, and United States. However, uncertainty remains regarding the optimal size of the NGS panel to be used in daily practice.”³⁷

National Institute for Health and Care Excellence (NICE)

The NICE has provided guidance for EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer.

“1.1 The tests and test strategies listed below are recommended as options for detecting epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations in the tumours of adults with previously untreated, locally advanced or metastatic non-small-cell lung cancer (NSCLC), when used in accredited laboratories participating in an external quality assurance scheme. The laboratory-developed tests should be designed to detect the mutations that can be detected by one of the CE-marked tests as a minimum.

- theascreen EGFR RGQ PCR Kit (CE-marked, Qiagen)
- cobas EGFR Mutation Test (CE-marked, Roche Molecular Systems)
- Sanger sequencing of samples with more than 30% tumour cells and theascreen EGFR RGQ PCR Kit for samples with lower tumour cell contents
- Sanger sequencing of samples with more than 30% tumour cells and cobas EGFR Mutation Test for samples with lower tumour cell contents
- Sanger sequencing followed by fragment length analysis and polymerase chain reaction (PCR) of negative samples.

1.2 There was insufficient evidence for the Committee to make recommendations on the following methods:

- high-resolution melt analysis
- pyrosequencing combined with fragment length analysis
- single-strand conformation polymorphism analysis
- next-generation sequencing
- theascreen EGFR Pyro Kit (CE-marked, Qiagen).³⁸

International Association for the Study of Lung Cancer (IASLC)

The IASLC released consensus recommendations on Neoadjuvant and Adjuvant Treatments for early-stage Resectable NSCLC. “In the light of ongoing trials in populations with specific driver alterations and with extrapolation of the limited efficacy of PD-1 and PD-L1 inhibitors in patients with driver alterations, in addition to assessing *EGFR* and *ALK* alteration status, biomarker testing for other oncogenic drivers is highly encouraged in patients with early-stage disease.” The IASLC also states that “Regarding the type and extent of molecular testing in patients with early-stage disease, testing by next-generation sequencing (NGS) is preferred due to the opportunity to effectively detect all actionable genomic alterations.” The IASLC further explains that “Although single-gene testing is frequently performed to assess *EGFR* and *ALK* mutation status, NGS is more efficient for evaluating actionable gene alterations in all nine established biomarkers simultaneously. Compared with sequential single-gene testing, NGS can yield results for all nine biomarkers in a shorter time, uses less tissue, and avoids administration of PD-

1 and PD-L1 inhibitors (and associated adverse effects) that may not be as effective as targeted molecular therapies.”³⁹

VII. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

VIII. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
81194	NTRK (neurotrophic receptor tyrosine kinase 1, 2, and 3) (eg, solid tumors) translocation analysis
81210	BRAF (B-Raf proto-oncogene, serine/threonine kinase) (eg, colon cancer, melanoma), gene analysis, V600 variant(s)
81235	EGFR (epidermal growth factor receptor) (eg, non-small cell lung cancer) gene analysis, common variants (eg, exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)
81275	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; variants in exon 2 (eg, codons 12 and 13)
81276	KRAS (Kirsten rat sarcoma viral oncogene homolog) (eg, carcinoma) gene analysis; additional variant(s) (eg, codon 61, codon 146)
81404	Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)
81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)
81406	Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons)
81445	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis
81449	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis

81455	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis
81456	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis
81479	Unlisted molecular pathology procedure
88360	Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure; manual
88361	Morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure; using computer-assisted technology
0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score Proprietary test: RiskReveal™ Lab/Manufacturer: Razor Genomics
0414U	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker Proprietary test: LungOI Lab/Manufacturer: Imagene
0478U	Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and reported as actionable detected variants for therapy selection Proprietary test: Lung HDPCR™ Lab/Manufacturer: Protean BioDiagnostics

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

IX. Evidence-based Scientific References

1. Thomas KW, Gould MK, Naegar D. Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer. Updated January 15, 2025. <https://www.uptodate.com/contents/overview-of-the-initial-evaluation-diagnosis-and-staging-of-patients-with-suspected-lung-cancer>

2. Neal JW. Personalized, genotype-directed therapy for advanced non-small cell lung cancer. Updated March 31, 2025. <https://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-lung-cancer>
3. ACS. What Is Non-Small Cell Lung Cancer? Updated January 20, 2024. <https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html>
4. Teixidó C, Vilariño N, Reyes R, Reguart N. PD-L1 expression testing in non-small cell lung cancer. *Therapeutic advances in medical oncology*. 2018;10:1758835918763493. doi:10.1177/1758835918763493
5. Fong KM, Zimmerman PV, Smith PJ. Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. *Cancer research*. Jan 1 1995;55(1):28-30.
6. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. *Therapeutic advances in respiratory disease*. 2016;10(2):113-29. doi:10.1177/1753465815617871
7. Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. *Journal for ImmunoTherapy of Cancer*. 2018;6(1):35. doi:10.1186/s40425-018-0342-x
8. Lemery S, Keegan P, Pazdur R. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. *The New England journal of medicine*. 2017;377(15):1409-1412. doi:10.1056/NEJMp1709968
9. FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
10. FDA. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). <https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools>
11. Guardant. Guardant360® CDx liquid biopsy is helping to bring the promise of precision oncology to more advanced cancer patients. https://guardanthealth.com/wp-content/uploads/Guardant360_CDx_Background Document.pdf
12. FDA. cobas EGFR Mutation Test v2. <https://www.fda.gov/drugs/resources-information-approved-drugs/cobas-egfr-mutation-test-v2>
13. Lin JH, Lin D, Xu L, et al. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations. *Oncotarget*. 2017;8(2):3412-3421. doi:10.18632/oncotarget.13787
14. Li X, Cai W, Yang G, et al. Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. 2017;12(9):1388-1397. doi:10.1016/j.jtho.2017.06.006
15. Wang Z, Yang H, Luo S, et al. Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis. *Lung cancer (Amsterdam, Netherlands)*. 2017;112:1-9. doi:10.1016/j.lungcan.2017.07.029
16. Gainor JF, Shaw AT, Sequist LV, et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2016;22(18):4585-93. doi:10.1158/1078-0432.Ccr-15-3101
17. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *The Lancet Oncology*. 2016;17(7):984-993. doi:10.1016/s1470-2045(16)30146-2

18. Singal G, Miller PG, Agarwala V, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. *Jama*. 2019;321(14):1391-1399. doi:10.1001/jama.2019.3241
19. Siena S, Doebele RC, Shaw AT, et al. Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. *Journal of Clinical Oncology*. 2019;37(15_suppl):3017-3017. doi:10.1200/JCO.2019.37.15_suppl.3017
20. Volckmar AL, Leichsenring J, Kirchner M, et al. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. *Int J Cancer*. 2019;145(3):649-661. doi:10.1002/ijc.32133
21. Signorovitch J, Zhou Z, Ryan J, Anhorn R, Chawla A. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. *J Med Econ*. 2019;22(2):140-150. doi:10.1080/13696998.2018.1549056
22. Peled M, Bar J, Avni L, et al. Early Blood-based Liquid Biopsy in Patients with Treatment-naïve Metastatic Adenocarcinoma of the Lung: A Case Series. *Isr Med Assoc J*. 2020;22(12):784-787.
23. Al-Ahmadi A, Ardeshtir-Larijani F, Fu P, et al. Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. *Clinical Lung Cancer*. 2021;22(1):16-22.e1. doi:10.1016/j.clcc.2020.08.004
24. Boeckx B, Shahi RB, Smeets D, et al. The genomic landscape of nonsmall cell lung carcinoma in never smokers. *Int J Cancer*. 2020;146(11):3207-3218. doi:10.1002/ijc.32797
25. Qi Z, Ha T, Feng W, et al. Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies. *Arch Pathol Lab Med*. Sep 20 2024;doi:10.5858/arpa.2024-0014-OA
26. Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. Jan 23 2023;doi:10.1016/j.annonc.2022.12.009
27. Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis. *Mol Diagn Ther*. Sep 2024;28(5):525-536. doi:10.1007/s40291-024-00725-x
28. NCCN. NCCN Clinical Practice Guidelines in Oncology; Non-Small Cell Lung Cancer v3.2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
29. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *The Journal of molecular diagnostics : JMD*. 2018;20(2):129-159. doi:10.1016/j.jmoldx.2017.11.004
30. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. *Arch Pathol Lab Med*. 2013;137(6):828-60. doi:10.5858/arpa.2012-0720-OA
31. Hanna NH, Robinson AG, Temin S, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. *Journal of Clinical Oncology*. 2021;39(9):1040-1091. doi:10.1200/jco.20.03570
32. Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical

Oncology/Cancer Care Ontario Clinical Practice Guideline Update. *J Clin Oncol*. Sep 1 2017;35(25):2960-2974. doi:10.1200/jco.2017.72.4401

33. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. *Journal of Clinical Oncology*. 2018/03/20 2018;36(9):911-919. doi:10.1200/JCO.2017.76.7293
34. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2016;doi:10.1093/annonc/mdw326
35. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2017;28(suppl_4):iv1-iv21. doi:10.1093/annonc/mdx222
36. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2020;29(Suppl 4):iv192-iv237. doi:10.1093/annonc/mdy275
37. Mosele MF, Westphalen CB, Stenzinger A, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. *Ann Oncol*. Jul 2024;35(7):588-606. doi:10.1016/j.annonc.2024.04.005
38. NICE. EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. Updated August 14, 2013. <https://www.nice.org.uk/guidance/dg9/chapter/1-Recommendations>
39. Spicer JD, Cascone T, Wynes MW, et al. Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*. Oct 2024;19(10):1373-1414. doi:10.1016/j.jtho.2024.06.010

X. Review/Revision History

Effective Date	Summary
10/15/2025	<p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>Edited CC1 to reflect that single gene or broad molecular profiling of the tumor tissue is allowed. Now reads: “1) For individuals with non-small cell lung cancer (NSCLC), single gene testing or broad molecular profiling of the tumor tissue to identify established actionable driver mutations (see Note 1) MEETS COVERAGE CRITERIA.”</p> <p>Changes in CC1 results in updates to CC4, now reads: “4) To direct targeted therapy for individuals with NSCLC, the following testing DOES NOT MEET COVERAGE CRITERIA:</p> <ul style="list-style-type: none"> a) Single gene analysis for genetic alterations not found in Note 1. b) Broad molecular profiling panels that do not include the minimum genetic variants addressed in Note 1.” <p>Results in addition of new Note 1 to define the minimum gene set required when performing broad molecular profiling: “Note 1: When broad molecular profiling is performed in individuals with NSCLC, the molecular profiling panel must at minimum include the following genetic variants: ALK rearrangements, BRAF</p>

	<p>mutations, EGFR mutations, ERBB2 (HER2) mutations, KRAS mutations, METex14 skipping mutations, NTRK1/2/3 gene fusions, RET rearrangements, and ROS1 rearrangements. It is recommended that the profiling panel also include emerging biomarkers for which effective therapy may be available (e.g., high-level MET amplifications)."</p> <p>Former Note, now Note 2, change "2" to "two" for consistency.</p> <p>Added CPT code 81445, 81449, 81455, 81456</p> <p>Removed CPT code 88342</p>
12/01/2024	<p>Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria. The following changes were made for clarity and consistency:</p> <p>Note was updated to reflect changes to Avalon's definition of a genetic panel within R2162. Now reads: "Note: For 2 or more gene tests being run on the same platform, please refer to AHS-R2162-Reimbursement Policy."</p>
12/01/2024	Initial Policy Implementation